Zelira Therapeutics Share Price and Company Fundamentals

-0.001 (-2.222%)
52 week
0.043 - 0.14

Last traded: Yesterday at 5:54 AM

Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the development of cannabinoid-based formulations for the treatment of various medical conditions in Australia. It offers formulations under the HOPE brand in Pennsylvania and licenses in Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. The company is also involved in a human clinical trial program focused on insomnia, autism, and opioid reduction; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer, as well as the potential for cannabinoid formulations to treat diabetes-associated cognitive decline. It has a strategic partnership with CannPal Pty Ltd; and St Vincent's Hospital on opioid reduction study. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited is based in Perth, Australia.

Key Metrics

PE ratio


PB ratio


Dividend yield



Market cap


Enterprise value


Company profile

Primary activitiesBio-pharmaceutical
Industry / SectorBiotechnology / Healthcare
Mailing address101 St Georges Terrace Level 3 Perth WA 6000 Australia
Phone / Fax61 8 6558 0886 / 61 8 6316 3337


Zelira Therapeutics does not pay dividends.

Company Executives

As of Jul 2021, following are the company executives and directors listed on Zelira Therapeutics.

NameTitleAgeTotal Pay
Mr. Osagie O. ImasogieFounder & Chairman5884k
Mr. Harry Karelis B.Sc (Hons), MBA, CFA, F.Fin, FAICDCo-Founder & Non-Exec. Deputy Chairman50120k
Mr. Jason William PetersonCo-Founder & Non-Exec. Director36k
Dr. Oludare OdumosuCEO of USA, MD of USA & Director196.86k
Mr. Timothy Ryan SlateCompany Sec.
Dr. Patty WasherClinical Trial Consultant

Profitability and management effectiveness

Profit margin


Operating margin


Return on assets


Return on equity


Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Zelira Therapeutics is 52.37M and its enterprise value is 45.22M. The enterprise value to revenue ratio of ZLD is 42.17.

The ZLD's stocks Beta value is 1.11 making it 11% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Zelira Therapeutics (ZLD)

Zelira Therapeutics (ASX:ZLD) Frequently Asked Questions

1. What is Zelira Therapeutics's Stock Symbol?

Zelira Therapeutics trades on ASX under the ticker symbol "ZLD".

2. What is Zelira Therapeutics's stock price today?

One share of ZLD stock can currently be purchased for approximately $0.044.

3. How can I contact Zelira Therapeutics?

Zelira Therapeutics's mailing address is 101 St Georges Terrace Level 3 Perth WA 6000 Australia. The company can be reached via phone at 61 8 6558 0886.

4. What is Zelira Therapeutics's official website?

The official website of Zelira Therapeutics is http://www.zeliratx.com.

5. Which share registry manages Zelira Therapeutics's stock?

Zelira Therapeutics's stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.